帕曲妥單抗

化合物

帕曲妥單抗INN:Patritumab)是一種人單株抗體,設計用於治療非小細胞肺癌英語Non-small-cell lung cancer。它充當免疫調節劑[1][2]

帕曲妥單抗
單株抗體
種類完整抗體
目標HER3英語ERBB3
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號1262787-83-6
ChemSpider
  • none
UNII
KEGG

臨床試驗

編輯

它正在進行針對頭頸部鱗狀細胞癌的二期臨床試驗。[3]

它將被納入I-SPY 2乳腺癌試驗的新組中。[4]

參考資料

編輯
  1. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 (PDF). WHO Drug Information. 2011, 25 (4) [2024-01-24]. (原始內容存檔 (PDF)於2016-03-04). 
  2. ^ Horinouchi H. The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy. December 2016, 16 (12): 1549–1555. PMID 27744717. S2CID 4035336. doi:10.1080/14712598.2016.1249846. 
  3. ^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
  4. ^ Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer. October 2016 [2024-01-24]. (原始內容存檔於2024-01-24).